Skip to main content
Log in

Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Duchenne and Becker muscular dystrophy (DMD and BMD, respectively) are allelic disorders with different clinical presentations and severity determined by mutations in the gene DMD, which encodes the sarcolemmal protein dystrophin. Diagnosis is based on clinical aspects and muscle protein analysis, followed by molecular confirmation. We revised the main aspects of the natural history of dystrophinopathies to define genotype–phenotype correlations in large patient cohorts with extended follow-up. We also specifically explored subjects carrying nucleotide substitutions in the DMD gene, a comparatively less investigated DMD/BMD subgroup. We studied 320 dystrophinopathic patients (205 DMD and 115 BMD), defining muscular, cardiac, respiratory, and cognitive involvement. We also subdivided patients according to the kind of molecular defect (deletions, duplications, nucleotide substitutions or other microrearrangements) and the mutation sites (proximal/distal to exon 45), studying phenotype–genotype correlations for each group. In DMD, mutation type did not influence clinical evolution; mutations located in distal regions (irrespective of their nature) are more likely to be associated with lower IQ levels (p = 0.005). BMD carrying proximal deletions showed a higher degree of cardiac impairment than BMD with distal deletions (p = 0.0046). In the BMD population, there was a strong correlation between the entity of muscle dystrophin deficiency and clinical course (p = 0.002). An accurate knowledge of natural history may help in the clinical management of patients. Furthermore, several clinical trials are ongoing or are currently planned, some of which aim to target specific DMD mutations: a robust natural history is therefore essential to correctly design these experimental trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Davies KE, Smith TJ, Bundey S, Read AP, Flint T, Bell M, Speer A (1988) Mild and severe muscular dystrophy associated with deletions in Xp21 of the human X chromosome. J Med Genet 25:9–13

    Article  PubMed  CAS  Google Scholar 

  2. Comi GP, Prelle A, Bresolin N, Moggio M, Bardoni A, Gallanti A, Vita G, Toscano A, Ferrò MT, Bordoni A et al (1994) Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. Brain 117:1–14

    Article  PubMed  Google Scholar 

  3. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, Angelini C, Sugita H, Kunkel LM (1991) Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 49:54–67

    PubMed  CAS  Google Scholar 

  4. Béroud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, Moizard MP, Voelckel MA, Calemard LM, Boisseau P, Blayau M, Philippe C, Cossée M, Pagès M, Rivier F, Danos O, Garcia L, Claustres M (2007) Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat 28:196–202

    Article  PubMed  Google Scholar 

  5. Emery AE (1994) Some unanswered questions in Duchenne muscular dystrophy. Neuromuscul Disord 4:301–303

    Article  PubMed  CAS  Google Scholar 

  6. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, Müller CR, Lindlöf M, Kaariainen H et al (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45:498–506

    PubMed  CAS  Google Scholar 

  7. Todorova A, Todorov T, Georgieva B, Lukova M, Guergueltcheva V, Kremensky I, Mitev V (2008) MLPA analysis/complete sequencing of the DMD gene in a group of Bulgarian Duchenne/Becker muscular dystrophy patients. Neuromuscul Disord 18:667–670

    Article  PubMed  Google Scholar 

  8. Desguerre I, Christov C, Mayer M, Zeller R, Becane HM, Bastuji-Garin S, Leturcq F, Chiron C, Chelly J, Gherardi RK (2009) Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS One 4:e4347

    Article  PubMed  Google Scholar 

  9. Deburgrave N, Daoud F, Llense S, Barbot JC, Récan D, Peccate C, Burghes AH, Béroud C, Garcia L, Kaplan JC, Chelly J, Leturcq F (2007) Protein- and mRNA-based phenotype–genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat 28:183–195

    Article  PubMed  CAS  Google Scholar 

  10. Manzur AY, Kuntzer T, Pike M, Swan A (2008). Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 23(1):CD003725

    Google Scholar 

  11. Kaspar RW, Allen HD, Montanaro F (2009) Current understanding and management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy. J Am Acad Nurse Pract 21:241–249

    Article  PubMed  Google Scholar 

  12. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K (2002) Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 12:926–929

    Article  PubMed  Google Scholar 

  13. Nelson SF, Crosbie RH, Miceli MC, Spencer MJ (2009) Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr Opin Neurol 22:532–538

    Article  PubMed  Google Scholar 

  14. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87–91

    Article  PubMed  CAS  Google Scholar 

  15. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL (2007) Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. Clin Pharmacol 47:430–444

    Article  CAS  Google Scholar 

  16. Hammond SM, Wood MJ (2010) PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy. Curr Opin Mol Ther 12:478–486

    PubMed  CAS  Google Scholar 

  17. Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A (2009) In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11:257–266

    Article  PubMed  CAS  Google Scholar 

  18. Muntoni F, Bushby KD, van Ommen G (2008) 149th ENMC International Workshop and 1st TREAT-NMD Workshop on: “planning phase i/ii clinical trials using systemically delivered antisense oligonucleotides in duchenne muscular dystrophy”. Neuromuscul Disord 18:268–275

    Article  PubMed  Google Scholar 

  19. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda ME, Rutherford M, McCulley C, Popplewell L, Graham IR, Dickson G, Wood MJ, Wells DJ, Wilton SD, Kole R, Straub V, Bushby K, Sewry C, Morgan JE, Muntoni F (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8:918–928

    Article  PubMed  CAS  Google Scholar 

  20. Tuffery-Giraud S, Béroud C, Leturcq F, Yaou RB, Hamroun D, Michel-Calemard L, Moizard MP, Bernard R, Cossée M, Boisseau P, Blayau M, Creveaux I, Guiochon-Mantel A, de Martinville B, Philippe C, Monnier N, Bieth E, Khau Van Kien P, Desmet FO, Humbertclaude V, Kaplan JC, Chelly J, Claustres M (2009) Genotype–phenotype analysis in 2, 405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat 30:934–945

    Article  PubMed  CAS  Google Scholar 

  21. Brabec P, Vondrácek P, Klimes D, Baumeister S, Lochmüller H, Pavlík T, Gregor J (2009) Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. Neuromuscul Disord 19:250–254

    Article  PubMed  Google Scholar 

  22. American Academy of Orthopedic Surgeons (1965) Joint motion: method of measuring and recording. London, Churchill Livingston

    Google Scholar 

  23. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J (2005) Interpretative strategies for lung function tests. Eur Respir J 26:948–968

    Article  PubMed  CAS  Google Scholar 

  24. Nicholson LV, Davison K, Johnson MA, Slater CR, Young C, Bhattacharya S, Gardner-Medwin D, Harris JB (1989) Dystrophin in skeletal muscle. II. Immunoreactivity in patients with Xp21 muscular dystrophy. J Neurol Sci 94:137–146

    Article  PubMed  CAS  Google Scholar 

  25. Prelle A, Comi GP, Tancredi L et al (1998) Sarcoglycan deficiency in a large Italian population of myopathic patients. Acta Neuropathol 96:509–514

    Article  PubMed  CAS  Google Scholar 

  26. Minetti C, Sotgia F, Bruno C et al (1998) Mutations in the caveolin-3 gene cause autosomal dominant limb–girdle muscular dystrophy. Nat Genet 18:365–368

    Article  PubMed  CAS  Google Scholar 

  27. Valle G, Faulkner G, De Antoni A et al (1997) Telethonin, a novel sarcomeric protein of heart and skeletal muscle. FEBS Lett 415:163–168

    Article  PubMed  CAS  Google Scholar 

  28. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57

    Article  PubMed  Google Scholar 

  29. Den Dunnen JT, Antonarakis SE (2000) Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 15:7–12

    Article  Google Scholar 

  30. Consensus conference (1999) Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation—a consensus conference report. Chest 116:521–534

    Article  Google Scholar 

  31. Finsterer J (2006) Cardiopulmonary support in Duchenne muscular dystrophy. Lung 184:205–215

    Article  PubMed  Google Scholar 

  32. Felisari G, Martinelli Boneschi F, Bardoni A, Sironi M, Comi GP, Robotti M, Turconi AC, Lai M, Corrao G, Bresolin N (2000) Loss of Dp140 dystrophin isoform and intellectual impairment in Duchenne dystrophy. Neurology 55:559–564

    PubMed  CAS  Google Scholar 

  33. D’Angelo MG, Bresolin N (2006) Cognitive impairment in neuromuscular disorders. Muscle Nerve 34:16–33

    Article  PubMed  Google Scholar 

  34. Daoud F, Angeard N, Demerre B, Martie I, Benyaou R, Leturcq F, Cossée M, Deburgrave N, Saillour Y, Tuffery S, Urtizberea A, Toutain A, Echenne B, Frischman M, Mayer M, Desguerre I, Estournet B, Réveillère C, Penisson-Besnier, Cuisset JM, Kaplan JC, Héron D, Rivier F, Chelly J (2009) Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. Hum Mol Genet 18:3779–3794

    Article  PubMed  CAS  Google Scholar 

  35. Cunniff C, Andrews J, Meaney FJ, Mathews KD, Matthews D, Ciafaloni E, Miller TM, Bodensteiner JB, Miller LA, James KA, Druschel CM, Romitti PA, Pandya S (2009) Mutation analysis in a population-based cohort of boys with Duchenne or Becker muscular dystrophy. J Child Neurol 24:425–430

    Article  PubMed  Google Scholar 

  36. Nigro G, Politano L, Nigro V, Petretta VR, Comi LI (1994) Mutation of dystrophin gene and cardiomyopathy. Neuromuscul Disord 4:371–379

    Article  PubMed  CAS  Google Scholar 

  37. Bullam DE, Murphy EG, Zubrycka-Gaan EE et al (1991) Differentiation of Duchenne and Becker muscular dystrophy with amino- and carboxy terminal antisera specific for dystrophin. Am J Hum Mol Genet 48:295

    Google Scholar 

  38. Arahata K, Beggs AH, Honda H, Ito S, Ishiura S, Tsukahara T, Ishiguro T, Eguchi C, Orimo S, Arikawa E et al (1991) Preservation of the C-terminus of dystrophin molecule in the skeletal muscle from Becker muscular dystrophy. J Neurol Sci 101:148–156

    Article  PubMed  CAS  Google Scholar 

  39. Finsterer J, Stöllberger C (2003) The heart in human dystrophinopathies. Cardiology 99:1–19

    Article  PubMed  Google Scholar 

  40. Novaković I, Bojić D, Todorović S, Apostolski S, Luković L, Stefanović D, Milasin J (2005) Proximal dystrophin gene deletions and protein alterations in Becker muscular dystrophy. Ann NY Acad Sci 1048:406–410

    Article  PubMed  Google Scholar 

  41. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de Kimpe SJ, Ekhart PF, Venneker EH, Platenburg GJ, Verschuuren JJ, van Ommen GJ (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357:2677–2686

    Article  PubMed  Google Scholar 

  42. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30:293–299

    Article  PubMed  Google Scholar 

  43. Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, Harper HA, Robinson AS, Engelhardt JF, Brooks SV, Chamberlain JS (2002) Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 8:253–261

    Article  PubMed  CAS  Google Scholar 

  44. Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, Chamberlain JS (1995) Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 4:1251–1258

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We wish to thank the patients and their families for their support and collaboration. This research received funding support from Telethon—UILDM Grant GUP07009 (GPC). Telethon Genetic Biobanks Network GTB07001E was the source of the DNA used in this study. Eurobiobank project QLTR-2001-02769 is also gratefully acknowledged. Telethon North Star.

Conflict of interest

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Giacomo Pietro Comi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Magri, F., Govoni, A., D’Angelo, M.G. et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol 258, 1610–1623 (2011). https://doi.org/10.1007/s00415-011-5979-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-011-5979-z

Keywords

Navigation